Introduction
============

Thyroid disorders are among the most prevalent diseases in the western world, affecting as many as one out of seven adults [@bib1]. They are frequently associated with overt thyroid dysfunction, particularly various degrees of hypothyroidism that require thyroid hormone replacement [@bib2]. This is mainly done by administration of synthetic levothyroxine ([l]{.smallcaps}-T~4~), which is a well-established, convenient, safe and inexpensive treatment modality [@bib4]. However, this does not accurately reflect the natural direct secretion pattern of both thyroid hormones triiodothyronine (T~3~) and thyroxine (T~4~) by the thyroid gland [@bib6]. Unlike other drugs, dosing of [l]{.smallcaps}-T~4~ is not fixed but has to be titrated according to individual needs. Dose adequacy is mainly defined by reference to suitable biochemical standards, particularly thyrotropin (TSH) [@bib8]. This parameter has evolved into the main treatment target to be monitored and kept within an assumed euthyroid range [@bib9]. A number of studies have attempted to predict T~4~ requirement, and various regimes for a starting dose have been proposed based on an average of 1.6 μg/kg body weight (BW) or by more refined weight- or BMI-related algorithms [@bib10].

Although TSH measurement has dominated procedural management of thyroid replacement by its apparent ease and good standardisation, a disturbingly high proportion of patients remains unsatisfied with the treatment they receive [@bib17]. This has prompted some authors including our group to question the validity of relying on the TSH level as the sole measure of dose adequacy in [l]{.smallcaps}-T~4~-treated patients [@bib19]. We have shown that the homeostatic equilibria between TSH and peripheral thyroid hormones are modulated by various influences such as age, body mass and the treatment modality itself [@bib22]. As a controlling element, the effective TSH level derived in a healthy normal population cannot necessarily be inferred to be equally optimal for a given patient on [l]{.smallcaps}-T~4~ medication, because the constitutive equilibria between TSH and thyroid hormones, especially FT~3~, differ in health and disease [@bib22].

In the present analysis, we examined the relationship of the [l]{.smallcaps}-T~4~ dose with clinical categories and biochemical outcomes such as TSH, FT~4~ and FT~3~ levels. We sought to define the interaction between TSH and the FT~3~ target and also to analyse the influences of modulators such as gender, age, disease category or the efficiency of T~3~ conversion from T~4~.

Subjects and methods
====================

Study design and objective
--------------------------

An open prospective observational study (ClinicalTrials.gov NCT01969552) was conducted at the Department of Nuclear Medicine at Klinikum Luedenscheid, Germany, between July 2013 and February 2014 and approved by the Ethics Committee of the University of Muenster, Germany. Participants gave written informed consent.

The present secondary analysis is restricted to the subgroup of patients on steady [l]{.smallcaps}-T~4~ treatment, examining dose requirements of [l]{.smallcaps}-T~4~ including conditioning modulators, thyroid hormone conversion efficiency and relationships with biochemical outcomes such as TSH, FT~4~ and FT~3~ levels. The primary study outcome, namely the analysis of the interacting equilibria and interrelations between thyroid parameters under various conditioning influences such as gender, age and body mass and [l]{.smallcaps}-T~4~ treatment has already been reported [@bib22].

Patients
--------

The original study involved 1912 adult patients who were consecutively seen, were free of severe comorbidity and provided written informed consent. For this subgroup analysis, 353 patients on thyroid hormone replacement meeting the following criteria were included: being seen as outpatients, presenting in a controlled functional state (FT~4~ ≥10 pmol/l and TSH ≤4 mU/l) and having reached a steady state on a constant [l]{.smallcaps}-T~4~ medication. Although infrequently seen in an ambulatory setting, patients with severe non-thyroidal illness or potentially interfering comorbidities were ineligible to participate in the study. This exclusion extended to other conditions and the use of comedications that may interfere with the resorption or measurement of thyroid hormones or with pituitary TSH. Patients with T~3~/T~4~ combination therapy (*n*=9), anti-thyroid drug use (*n*=99), hypothalamic/pituitary diseases (*n*=5) or pregnancy (*n*=3) were excluded before analysis.

Diagnostic procedures included a detailed history, physical examination, standardised questionnaire documenting gender, age, height, weight, smoking habits (75% answered), prior surgery or radioiodine treatment, thyroid medication (brand, dosage, duration, time of intake), other drugs, laboratory tests (FT~3~, FT~4~, TSH and, if autoimmune thyroiditis was suspected or to be excluded, thyroid peroxidase antibodies (TPO-Ab) or TSH-receptor antibodies (TSH-R Ab)) and thyroid imaging.

Laboratory methods
------------------

TSH, FT~3~ and FT~4~ were measured with an automated direct chemoluminescence method (Advia Centaur XP, Siemens Healthcare Diagnostics, Erlangen, Germany). TSH is traceable to the 3rd International Standard for TSH (WHO, IRP 81/565). A TSH range from 0.006 to 160 mU/l was linear, and coefficient of variations of inter-assay imprecision ranged from 0.9% to 2.4%. Reference intervals were laboratory established and pre-evaluated for the local population, using 10--23 pmol/l for FT~4~, 3.1--6.8 pmol/l for FT~3~ and 0.4--4.0 mU/l for TSH [@bib23].

TPO-Abs were determined by a competitive chemoluminescence method (ADVIA Centaur XP, Siemens Healthcare Diagnostics, reference range \<60 U/ml) and TSH-R Abs by competitive ELISA (Euroimmun AG, Lübeck, Germany, reference range \<2 U/l).

FT~3~--FT~4~ ratio and calculated deiodinase activity
-----------------------------------------------------

As measures of conversion efficiency, we calculated the FT~3~--FT~4~ ratio by simple division of both parameters in pmol/l and the sum activity of peripheral deiodinases (SPINA-GD, termed 'deiodinase activity,' thereafter, nmol/s) from equilibrium levels of FT~4~, FT~3~ and estimated constant parameters for plasma protein binding, distribution and elimination with

as previously described [@bib20].

Although the two measures are closely related in the linear part of the substrate relationship defined by Michaelis-Menten kinetics, only the more complex formula (G~D~) accounts for the saturation kinetics of the enzyme.

In addition to using estimated deiodinase activity as a continuous variable, we divided deiodinase activity in three distinct categories defining poor (\<23 nmol/s), intermediate (23--29 nmol/s) or good (\>29 nmol/s) converters. The cut-offs were pre-specified based on observations in [l]{.smallcaps}-T~4~-treated patients vs healthy untreated subjects and in low (\<5 ml) vs higher thyroid volumes [@bib22]. They approximate turning points in the relationship between deiodinase activity and FT~3~, defining a central region with a derivative of about 0 and low or high regions with steeper slopes.

Thyroid ultrasound and scintigraphy
-----------------------------------

Thyroid volume was sonographically (10 MHz transducer) determined according to the ellipsoid formula. Reference values were \<18 ml for females and \<25 ml for males. A volume \<1 ml was considered athyreotic. Larger nodules were further examined by scintigraphy.

Statistical methods
-------------------

Descriptive data are reported as median plus interquartile range (IQR). We used Wilcoxon\'s rank sum or a *χ*^2^ test in case of categorical variables for comparison of baseline characteristics. Correlations are based on Pearson\'s product-moment when suitable or Kendall\'s *τ*. Multiple variables and conditional influences were analysed by a generalised linear model (GLM) and approximated by a linear regression function over restricted intervals. β coefficients were derived from a linear model. TSH was used after logarithmic transformation. We tested for collinearity in the models using the variance inflation factor. A GLM with a binomial function (logistic regression) was used to assess success rates of the [l]{.smallcaps}-T~4~ dose for reaching a TSH or FT~3~ target and to create dose-related probability plots. Relative proportions were statistically compared by receiver operating characteristic curves and Delong\'s test. *P* values \<0.05 were considered significant for all tests. Statistical analyses were performed using Deducer (version 0.7-7) and the R statistical package (Mac version 3.1.2) [@bib25].

Results
=======

The present analysis comprises 353 patients in a stable controlled non-hypothyroid state on thyroid hormone replacement with [l]{.smallcaps}-T~4~. Patient characteristics are shown in [Table 1](#tbl1){ref-type="table"}. Of the total study group, 304 patients were euthyroid according to FT~4~, 342 according to FT~3~ and 216 according to TSH, based on their respective reference intervals with all displaying clinically satisfactory levels of medication.

Dose requirements associated with biochemical euthyroidism (*n*=208) defined by the reference ranges of all three parameters varied widely from 25 to 275 μg/day [l]{.smallcaps}-T~4~ (mean 98, median 100 (IQR 75, 125)) or 0.3 to 2.2 μg/kg BW per day (mean 1.2, median 1.3 (IQR 0.94, 1.60)). In univariate linear models, the [l]{.smallcaps}-T~4~ dose in the treated euthyroid panel was significantly associated with gender, age, body mass index, aetiology of disease, T~3~--T~4~ ratio and calculated deiodinase activity (all *P*\<0.001) but not with TSH (*P*=0.94). The influences remained independently predictive in a multivariable model ([Table 2](#tbl2){ref-type="table"}).

TSH levels in the euthyroid range were unrelated to any of the above influences except disease category (*P*=0.003), as might be expected considering the lower TSH target in malignant disease. Deiodinase activity was positively associated with thyroid volume (*τ*=0.23, *P*\<0.001, *n*=208) but inversely correlated with weight-adjusted [l]{.smallcaps}-T~4~ dose (*r*=−0.37, *P*\<0.001, *n*=208).

In a biochemically defined euthyroid state excluding subclinically hyperthyroid subjects, athyreotic thyroid carcinoma patients received significantly higher doses of [l]{.smallcaps}-T~4~ (1.57 μg/kg BW per day (IQR 1.40, 1.69), *n*=50)) than patients with autoimmune thyroiditis (1.19 μg/kg BW per day (IQR 0.85, 1.47), *n*=76, *P*\<0.001)) or benign thyroid disease post surgery (1.08 μg/kg BW per day (IQR 0.82, 1.44), *n*=80, *P*\<0.001)). Furthermore, after adjusting for differing levels of TSH suppression in a linear model the weight-adjusted [l]{.smallcaps}-T~4~ dose was higher in athyreotic carcinoma patients compared to autoimmune thyroiditis or benign disease (*P*\<0.001, [Fig. 1](#fig1){ref-type="fig"}A). Similarly, the dose required to achieve the same FT~3~ concentration was higher in the carcinoma group (*P*\<0.001, [Fig. 1](#fig1){ref-type="fig"}B).

Median thyroid volume was 0 ml (IQR 0, 0 ml) in carcinomas, 7 ml (IQR 4, 11 ml) in autoimmune thyroiditis and 6 ml (IQR 3, 8 ml) in benign goitre post surgery. The weight-adjusted [l]{.smallcaps}-T~4~ dose was inversely correlated with the thyroid volume in the three diagnostic groups (*r*=−0.22, *P*=0.002, *n*=208).

Three distinct categories of conversion efficiency were defined (see Subjects and methods) as follows: poor converters \<23 nmol/s, intermediate converters 23--29 nmol/s and good converters \>29 nmol/s deiodinase activity. The poor converters reached significantly (*P*\<0.001) higher FT~4~ concentrations in the circulation than intermediate or good converters but, at the same time, showed significantly (*P*\<0.001) lower absolute FT~3~ levels compared to the other two groups ([Fig. 2](#fig2){ref-type="fig"}). While the FT~3~--FT~4~ dissociation was apparent in all three disease entities, it was most pronounced in the carcinoma group (*n*=143, [Fig. 2](#fig2){ref-type="fig"}). The latter group showed the highest proportion of poor converters ([Fig. 2](#fig2){ref-type="fig"}). The converter groups were similar (*P*\>0.1) in their age, BMI, weight-adjusted [l]{.smallcaps}-T~4~ dose and TSH levels except for men being overrepresented in the good converter group (*P*\<0.01). Converter categories of the carcinoma group were comparable (*P*=0.42) in their thyroid residual volumes, which were below 1 ml in 96% of all cases. In contrast, in the combined group of benign diseases the converter status was significantly associated with thyroid volume (4 [@bib2] vs 7 [@bib4] vs 8 [@bib5] ml, *P*=0.009). Thyroid volumes differed between the carcinoma group and the benign diseases (*P*\<0.001) but not between autoimmune thyroiditis and goitre post surgery (*P*=0.25, [Table 1](#tbl1){ref-type="table"}).

A given weight-adjusted dose suppressed the TSH below the lower reference limit (\<0.4 mU/l) in a higher proportion of carcinoma patients, than it raised their FT~3~ level above the median level typical of the euthyroid controls (\>5 pmol/l) ([Fig. 3](#fig3){ref-type="fig"}A and B). Conversely, much lower doses reached a target of a fully suppressed TSH compared to the FT~3~ median ([Fig. 3](#fig3){ref-type="fig"}A and B). The same tendency is true for a more modest target below 1 mU/l for TSH in autoimmune thyroiditis or benign disease post surgery, although variation was higher in this panel ([Fig. 3](#fig3){ref-type="fig"}C and D). Overall, a significantly higher proportion of patients achieved TSH suppression compared to FT~3~ above median by Delong\'s test employing receiver operating characteristic curves (*P*\<0.001).

Discussion
==========

In this cohort, dose requirements for [l]{.smallcaps}-T~4~-treated patients varied in a large euthyroid panel and were associated with many influences including gender, age, disease category and thyroid hormone conversion efficiency. However, not all of the treatment conditions necessarily aim at a biochemically euthyroid thyroid state as a comprehensive therapeutical goal, as defined by maintaining the respective reference ranges of all three parameters: TSH, FT~4~ and FT~3~. Particularly, in the treatment of thyroid carcinomas, for many patients in our sample the target was a lower or suppressed TSH below the reference range, which, as a consequence, raised FT~4~ levels above the upper reference range in a proportion of these patients. At both comparable levels of TSH suppression or similar FT~3~ concentrations, athyreotic thyroid carcinoma patients were taking a higher weight-adjusted dose of [l]{.smallcaps}-T~4~. Three remarkable and linked observations from this study were a dissociation between FT~3~ and FT~4~, an apparent disjoint between TSH and FT~3~ and an inverse association between [l]{.smallcaps}-T~4~ dose and conversion efficiency.

The present study was a cross-sectional secondary analysis not involving a randomised design. As previously reported in a separate communication [@bib22], the primary aim of this prospective observational study was to analyse further the interacting equilibria. While introducing some uncontrolled variations, this allowed for the study of a broader natural spectrum of responses, as observed in consecutive patients. FT~3~ or FT~4~ measurements were not compromised in any way by problematic conditions such as the non-thyroid illness syndrome, as the study was conducted in a cohort of otherwise 'healthy' out-patients without relevant comorbidity. There was no evidence for a potential bias stemming from a variable time interval between [l]{.smallcaps}-T~4~ intake and blood sampling, which might result in an expected slight temporary elevation of circulating FT~4~ concentrations, as previously discussed [@bib22]. There were neither linear (*P*=0.27) nor non-linear (*P*=0.28) relationships with deiodinase activity.

In [l]{.smallcaps}-T~4~ treatment, equilibria typical of the healthy state were found not to be invariant, but profoundly altered [@bib22]. Here we disclose further consequences that are associated with alterations in the regulatory patterns in patients under [l]{.smallcaps}-T~4~ therapy. In particular, one aspect relates to the [l]{.smallcaps}-T~4~ dose and conversion efficiency. We estimated T~4~--T~3~ conversion by calculating the sum activity of peripheral deiodinases (see Subjects and methods). The measure is similar to the FT~3~--FT~4~ ratio, albeit more precise wherein it accounts for non-linear enzyme saturation kinetics. However, it does not further differentiate global activity by type of deiodinase. Thus, the source of T~3~ or contribution of various tissues to the T~3~ plasma pool cannot be discerned. We found that a poor converter status was associated with a higher [l]{.smallcaps}-T~4~ dose and higher serum FT~4~ levels but still lower absolute FT~3~ concentrations, compared to the more efficient converters. This paradoxically relates the higher T~4~ supply to a worsened rather than improved absolute FT~3~ level. This is not to say that an increasing dose will not raise on average the FT~3~ but that the dose response varies widely among individuals, and conversion inefficiency in some patients may outweigh the dose effect in terms of achievable absolute FT~3~ concentrations. How can this be explained? A high [l]{.smallcaps}-T~4~ dose may not invariably remedy T~3~ deficiency owing to T~4~-induced conversion inefficiency but could actually hinder its attainment through the inhibitory actions of the substrate itself and/or reverse T~3~ (rT~3~) on deiodinase type 2 activity [@bib27]. A study by Cettour-Rose *et al*. [@bib28] confirmed that rT~3~, when infused into rats, inhibited deiodinase type 2 activity in the pituitary, cerebral cortex and brown adipose tissue, but interestingly, this did not have much impact on circulating T~4~, T~3~ and TSH concentrations in the animals. However, in this model the rT~3~ effect was studied under rather artificial conditions in the absence of an abundant T~4~ supply with elevated FT~4~ levels that characterizes the treatment situation. In contrast, another recent experimental study has shown that escalating only the [l]{.smallcaps}-T~4~ dose fails to normalize serum T~3~ in the rat, and as a result, irrespective of local variations by type of deiodinase, all organs examined such as the brain, liver and skeletal muscle were hypothyroid at the tissue level in the presence of a normal serum TSH [@bib29]. This study suggests ubiquitination may be the limiting factor for T~4~ alone to restore true tissue euthyroidism in the rodent [@bib29]. The lack of TSH stimulation and absence or functional deficiency of the thyroid gland may also impair T~4~--T~3~ conversion [@bib30]. Another important consideration is that, just as FT~4~ and FT~3~ dissociate under [l]{.smallcaps}-T~4~ therapy, so do TSH and FT~3~. While a high proportion of patients was able to achieve a target of a suppressed TSH below the lower reference limits or a TSH value \<1 mU/l in autoimmune thyroiditis, their FT~3~ levels at the same time frequently remained below the median FT~3~ level found in normal subjects. The situation differs from conditions in which [l]{.smallcaps}-T~4~ absorption may be impaired and, as a consequence, elevated TSH levels persist [@bib31]. Thus, not even an [l]{.smallcaps}-T~4~ dose in which TSH is fully suppressed and FT~4~ by far exceeds its upper reference limit can guarantee above average FT~3~ levels in these patients, indicating an FT~3~--TSH disjoint. As a consequence, although dose escalation may help some patients who maintained a sufficiently efficient thyroid hormone conversion to raise their FT~3~ for euthyroidism and well-being, the strategy may not be invariably successful in all patients. In two studies, ∼15% of athyreotic patients could not even raise their FT~3~ above the lower reference limit on [l]{.smallcaps}-T~4~ [@bib19]. Another controlled follow-up study after hemithyroidectomy for benign euthyroid goitre suggests that this deficiency may have unwanted clinical consequences. In this study, weight gain after 2 years in association with a lowered thyroid function within the laboratory reference range was interpreted as a clinical manifestation of a permanently decreased metabolic rate [@bib34].

[l]{.smallcaps}-T~4~ dose requirements have been well studied and various regimes based on weight, BMI or more refined algorithms have been proposed to put patients on a presumed adequate dose from the very beginning [@bib10]. As useful as these algorithms may be for average predictions and initial guidance in the general population, they do not take into account individual variations in the response to [l]{.smallcaps}-T~4~, such as conversion efficiency. Dosing strategies solely based on a TSH definition of euthyroidism neglect the important role of FT~3~, which has recently emerged as an equally significant parameter in defining thyroid physiology [@bib20]. Central and peripheral regulatory mechanisms do not constitute divided levels of control, as has previously been assumed. Rather they are integrated via feed-forward control of deiodinase activity by TSH and operate jointly to maintain T~3~ homeostasis as an overarching goal [@bib30].

While acknowledging the role of genetically determined differences in deiodinase activity affecting conversion rates, the poor converter status described here appears to emerge mainly as a consequence of the T~4~ monotherapy itself, induced by the mechanisms discussed above [@bib42]. Compared to untreated subjects, deiodinase activity and conversion efficiency tend to be diminished in [l]{.smallcaps}-T~4~ treatment [@bib20]. However, individual pre-treatment measurements were not available for comparison. We found conversion inefficiency to be significantly correlated with low residual thyroid volume and most prevalent in athyreotic patients. However, differences in deiodinase activities were also apparent in the absence of a functioning thyroid gland within the group of thyroidectomised carcinoma patients. Overall, patients differ widely in the degree of the conversion impairment they suffer. This, in turn, may influence their dose requirements of [l]{.smallcaps}-T~4~ and, at a comparable weight-adjusted [l]{.smallcaps}-T~4~ dose, their levels of TSH suppression and circulating FT~3~ concentrations.

We speculate that [l]{.smallcaps}-T~4~-induced conversion inefficiency could prevent some vulnerable subjects from reaching true tissue normality on T~4~ monotherapy alone. Those were not analysed separately in the numerous earlier T~3~/T~4~ trials and could be possible candidates for a combined T~3~/T~4~ treatment option, as recognized by some authors and the guidelines of the European Thyroid Association [@bib46]. As a limitation, this study addresses biochemical treatment responses but did not evaluate patient-reported outcomes or biomarkers of thyroid hormone action.

Whether conversion efficiency and the resulting differences in relationships between TSH, FT~4~ and FT~3~ are clinically useful markers of dosing inadequacy requires further well-designed prospective studies. Patient satisfaction, complaints and symptoms play an essential part in the clinical assessment. However, owing to considerable inter-individual variation, these measures apparently lack statistical power in a trial setting and have not been clearly linked to prognosis. For example, even a change in thyroid function as profound as the transition from the hypothyroid to the euthyroid state may be associated with only modest improvements in thyroid-related quality-of-life measures in patients with autoimmune thyroiditis [@bib48]. As a result, a trial size of several thousand subjects may be required to produce a credible result with adequate discriminatory power. Additionally, the exact outcome would depend on the overall makeup of the panel as regards the mixture of T~4~--T~3~ conversion capabilities. Possible long-term consequences of the observed biochemical alterations such as the altered FT~3~--FT~4~ ratio are also presently unknown.

The findings of the present study have several clinical implications. First, they recognize thyroid hormone conversion efficiency, as defined by the calculated global deiodinase activity or more simply the T~3~--T~4~ ratio, is an important determinant of [l]{.smallcaps}-T~4~ dose requirements and the biochemical response to treatment. Second, in view of a T~4~-related FT~3~--TSH disjoint, FT~3~ measurement should be adopted as an additional treatment target. Third, in cases where an FT~3~--FT~4~ dissociation becomes increasingly apparent following dose escalation of [l]{.smallcaps}-T~4~, an alternate treatment modality, possibly T~3~/T~4~ combination therapy, should be considered, but further randomized controlled trials are required to assess the benefit versus risk in this particular group.

The authors are grateful to Hans-Günther Wahl, Institute of Laboratory Medicine, Klinikum Lüdenscheid, for measuring thyroid hormones.

Declaration of interest
=======================

J W Dietrich is co-owner of the intellectual property rights for the patent 'System and Method for Deriving Parameters for Homeostatic Feedback Control of an Individual' (Singapore Institute for Clinical Sciences, Biomedical Sciences Institutes, Application Number 201208940e20120895). All other authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
=======

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

![TSH (A) or FT~3~ (B) vs weight-adjusted [l]{.smallcaps}-T~4~ dose in three groups of patients on thyroid hormone replacement, with autoimmune thyroiditis (*n*=96), after surgery for benign goitre (*n*=111) or thyroid carcinoma (*n*=143). Between group differences in both panels were significant (*P*\<0.01) and remained so after adjusting for volume (not shown, *P*\<0.01), as evidenced by linear models with the diagnostic group as a covariate. See text for further details. AIT, autoimmune thyroiditis; Goitre, goitre post surgery for benign nodular thyroid disease.](ec-04-196-g001){#fig1}

![FT~3~ (A), FT~4~ (B) and TSH (C) levels in [l]{.smallcaps}-T~4~-treated patients stratified by disease and conversion efficiency. The disease entities were closely associated with categories of the thyroid volume (see [Table 1](#tbl1){ref-type="table"} and text). The red box refers to poor converters (calculated deiodinase activity \<23 nmol/s), green to intermediate converters (deiodinase activity 23--29 nmol/s) and blue to good converters (deiodinase activity \>29 nmol/s). Remarkably, absolute FT~3~ concentrations were lowest in the poor converter group in all disease categories, while FT~4~ levels were highest in the poor converters. Wilcoxon test, revealed significant differences compared to each first group; \**P*\<0.05, \*\**P*\<0.001. AIT, autoimmune thyroiditis; goitre, goitre post surgery for benign nodular thyroid disease.](ec-04-196-g002){#fig2}

![Probability plot of weight adjusted [l]{.smallcaps}-T~4~ dose to (A) suppress TSH below its lower reference limit (0.4 mU/l) or (B) raise FT~3~ above the median of euthyroid controls (\>5 pmol/l) in the carcinoma patients (*n*=143), and (C) suppress TSH \<1 mU/l or (D) elevate FT~3~ above 5 pmol/l in benign disease (patients with autoimmune thyroiditis, *n*=75 and nodular thyroid disease post surgery, *n*=111). Probability plots were created by logistic regression. The shaded areas indicate the confidence interval surrounding the fitted curve. The TSH targets were more frequently reached at a lower dose than the FT~3~ target (see Results).](ec-04-196-g003){#fig3}

###### 

Characteristics of study group (*n*=353). For referencing purpose, parameters in 146 disease-free individuals from the same study were as follows: median age 38 (26, 49) years, TSH 1.62 (1.12, 2.25) mU/l, FT~3~ 5.0 (4.8, 5.2) pmol/l, FT~4~ 14.0 (13.0,15.1) pmol/l, calculated deiodinase activity 32.8 (30.0, 36.2) nmol/s, thyroid volume 10 (8,13) ml (22).

  **Parameter**                                           **Median (IQR) or percentage**
  ------------------------------------------------------- ----------------------------------------------------------
  Gender (female, male)                                   280 (79%), 73 (21%)
  Age (years)                                             56 (46, 66)
   In women vs men                                        53 (45, 66) vs 59 (53, 64), *P*=0.03
  Disease aetiology (%)                                   Autoimmune thyroiditis 27%
                                                          Benign thyroid disease after surgery 32%
                                                          Thyroid carcinoma[^a^](#tblfn1){ref-type="table-fn"} 41%
  Surgery, radioiodine treatment (%)                      73%, 42%
  BMI (kg/m^2^)                                           27.5 (24.1, 30.8)
  Dose (μg/day)                                           100 (75, 150)
  Weight-adjusted daily dose (μg/kg per day)              1.47 (1.09, 1.72)
  TSH (mU/l)                                              0.64 (0.12, 1.47)
  FT~3~ (pmol/l)                                          4.80 (4.40, 5.30)
  FT~4~ (pmol/l)                                          18.6 (16.2, 21.1)
  TPO-Ab (U/l)                                            450 (48, 1300), positive 65%, *n*=97
  FT~3~--FT~4~ ratio                                      0.26 (0.24, 0.29)
  Deiodinase activity (nmol/s)                            24.3 (21.8, 27.1)
  Thyroid volume (ml) -- total group                      2 (0, 7)
   Autoimmune thyroiditis                                 7 (4,11)
   Benign thyroid disease post surgery                    6 (2,10)
   Thyroid carcinoma[^b^](#tblfn2){ref-type="table-fn"}   0 (0, 0)

82% of the thyroid carcinoma patients had a higher TNM stage than 1.

96% had no detectable residual thyroid volume by ultrasound after total thyroidectomy and radioiodine treatment.

###### 

β coefficients in a linear model of covariates predicting dose of [l]{.smallcaps}-T~4~ in the euthyroid panel. The multivariable model was simultaneously fitted with the parameters listed, all of which were significant predictors of the [l]{.smallcaps}-T~4~ dose in univariate models. All variance inflations factors were \<1.2.

  **Variable**                          **β coefficient** (95% CI)
  ------------------------------------- ----------------------------------
  Gender male vs female                 0.22 (0.11, 0.33), *P*\<0.001
  Disease aetiology                     
   Autoimmune vs malignant disease      −0.33 (−0.47, −0.19), *P*\<0.001
   Benign goitre vs malignant disease   −0.34 (−0.48, −0.20), *P*\<0.001
  Age                                   −0.26 (−0.37, −0.15), *P*\<0.001
  BMI                                   0.33 (0.22, 0.44), *P*\<0.001
  Deiodinase activity                   −0.27 (−0.39, −0.15), *P*\<0.001
